Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion type Assertion NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_head.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion description "[The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion evidence source_evidence_literature NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion SIO_000772 23413279 NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion wasDerivedFrom befree-20150227 NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion wasGeneratedBy ECO_0000203 NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.